Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 54.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,173 shares of the biopharmaceutical company's stock after selling 19,434 shares during the period. Capstone Investment Advisors LLC's holdings in Catalyst Pharmaceuticals were worth $338,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in CPRX. JPMorgan Chase & Co. increased its position in Catalyst Pharmaceuticals by 9.1% during the third quarter. JPMorgan Chase & Co. now owns 408,261 shares of the biopharmaceutical company's stock worth $8,116,000 after buying an additional 33,888 shares during the period. Farther Finance Advisors LLC grew its position in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the last quarter. Allspring Global Investments Holdings LLC increased its holdings in shares of Catalyst Pharmaceuticals by 13.9% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 417,332 shares of the biopharmaceutical company's stock valued at $8,710,000 after acquiring an additional 50,888 shares during the period. Redhawk Wealth Advisors Inc. purchased a new stake in Catalyst Pharmaceuticals in the 4th quarter valued at $1,273,000. Finally, Spire Wealth Management boosted its stake in Catalyst Pharmaceuticals by 1,342.9% during the 4th quarter. Spire Wealth Management now owns 14,429 shares of the biopharmaceutical company's stock worth $301,000 after purchasing an additional 13,429 shares during the period. 79.22% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Brian Elsbernd sold 62,975 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $22.98, for a total value of $1,447,165.50. Following the transaction, the insider now directly owns 188,564 shares in the company, valued at approximately $4,333,200.72. This represents a 25.04 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the sale, the insider now directly owns 68,873 shares of the company's stock, valued at $1,521,404.57. The trade was a 39.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $23.06 on Wednesday. Catalyst Pharmaceuticals, Inc. has a 1 year low of $14.47 and a 1 year high of $26.16. The stock has a market capitalization of $2.81 billion, a price-to-earnings ratio of 19.54, a PEG ratio of 3.31 and a beta of 0.70. The stock has a fifty day moving average price of $22.95 and a two-hundred day moving average price of $22.36.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Baird R W raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Robert W. Baird upped their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research note on Monday, March 3rd. StockNews.com upgraded Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Stephens restated an "overweight" rating and set a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Finally, Bank of America reiterated a "buy" rating and issued a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, January 9th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.